Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Items 201–300 of 566
A Gut-Restricted Lithocholic Acid Analog as an Inhibitor of Gut Bacterial Bile Salt Hydrolases
Adhikari, A. A., Ramachandran, D., Chaudhari, S. N., Powell, C. E., Li, W., McCurry, M. D., Banks, A. S., & Devlin, A. S. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00192 · Cited by 54
Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes
Lamichhane, S., Sen, P., Dickens, A. M., Alves, M. A., Härkönen, T., Honkanen, J. K., Vatanen, T., Xavier, R. J., Hyötyläinen, T., Knip, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100762 · Cited by 61
“FXR and TGR5 signaling plays a critical role in regulation of systemic lipid, glucose, and energy homeostasis.(6,7) Dysregulation of systemic BA metabolism has been linked to multiple diseases, including fatty liver disease, cardiovascular disease, and type 2 diabetes.”
BackgroundCeramides are fuel gauges on the drive to cardiometabolic disease
Wilkerson, J. L., Tatum, S. M., Holland, W. L., & Summers, S. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00008.2023 · Cited by 67
NAFLD, Helicobacter species and the intestinal microbiome
Castaño‐Rodríguez, N., Mitchell, H. M., & Kaakoush, N. O. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.008 · Cited by 55
The pathophysiological function of non-gastrointestinal farnesoid X receptor
Yan, N., Yan, T., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107867 · Cited by 58
Self-citationRecent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
Ohtani, N., Kamiya, T., & Kawada, N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000241 · Cited by 63
Ma, J., Li, M., Bao, Y., Huang, W., He, X., Hong, Y., Wei, W., Liu, Z., Gao, X., Yang, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107361 · Cited by 54
Bile acid metabolism in type 2 diabetes mellitus
Sandoval, M. C., & Haeusler, R. A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01067-8 · Cited by 60
“After reports that some MCAs are FXR antagonists 77–79 , speculation rose that the natural presence of MCAs in mice might interfere with interpretation of FXR signalling studies in conventional mice.”
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 63
Intestinal bile acid receptors are key regulators of glucose homeostasis
Trabelsi, M.-S., Lestavel, S., Staels, B., & Collet, X. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665116002834 · Cited by 51
“Moreover, and according to the phenotype observed in whole-body FXR KO mice, intestinal specific FXR KO mice are protected against diet-induced obesity also through a reduction of intestinal ceramide production((88,89)).”
BackgroundResultInfluentialFarnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01247 · Cited by 55
“Mice with intestine-specific FXR disruption had August 2020 | Volume 11 | Article 1247 reduced hepatic triglyceride accumulation in response to a HFDinduced (Jiang et al., 2015a).”
BackgroundInfluentialBile acids as regulatory molecules and potential targets in metabolic diseases
Xie, A.-J., Mai, C.-T., Zhu, Y. Z., Liu, X., & Xie, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120152 · Cited by 54
Burris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 56
Recent advances in understanding noroviruses
Bartnicki, E., Cunha, J. B., Kolawole, A. O., & Wobus, C. E. (2017) · F1000Research · doi:10.12688/f1000research.10081.1 · Cited by 55
“Bile acids can directly induce ceramide production by activating the farnesoid X receptor (FXR) 77,78 , a nuclear receptor expressed in many tissues, including in the intestine and immune cells 79,80 .”
BackgroundZheng, Z., Zhao, Z., Li, S., Lu, X., Jiang, M., Lin, J., An, Y., Xie, Y., Xu, M., Shen, W., et al. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108829 · Cited by 54
“…KO mice displayed metabolic improvement (Prawitt et al., 2011; Gonzalez et al., 2015), and glycine-b -muricholic acid, a bile acid derivative and FXR antagonist, exhibited metabolic benefits in diet-induced and genetic obese mice through intestine-selective FXR antagonism (Jiang et al., 2015).”
BackgroundIntestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice
Bozadjieva-Kramer, N., Shin, J. H., Shao, Y., Gutiérrez‐Aguilar, R., Li, Z., Heppner, K. M., Chiang, S., Vargo, S. G., Granger, K., Sandoval, D. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24914-y · Cited by 52
Li, Y., Nicholson, R. J., & Summers, S. A. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111554 · Cited by 56
Xiang, D., Yang, J., Liu, L., Yu, H., Gong, X., & Liu, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115606 · Cited by 54
Chen, Y., Chaudhari, S. N., Harris, D. A., Roberts, C. F., Moscalu, A., Mathur, V., Zhao, L., Tavakkoli, A., Devlin, A. S., & Sheu, E. G. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.014 · Cited by 55
Ovadia, C., Perdones-Montero, A., Fan, H. M., Mullish, B. H., McDonald, J. A. K., Papacleovoulou, G., Wahlström, A., Ståhlman, M., Tsakmaki, A., Clarke, L. C. D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60821-w · Cited by 49
Zhuge, A., Li, S., Yuan, Y., Han, S., Xia, J., Wang, Q., Wang, S., Lou, P., Li, B., & Li, L. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102582 · Cited by 54
“One possible explanation is that accumulated ceramides in the liver, which is associated with activation of gut FXR pathway by OCA [71], accounts for poor insulin resistance [72,73].”
BackgroundThe role of bile acids in regulating glucose and lipid metabolism
Yu, H., Nie, R., & Shen, C. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0544 · Cited by 54
Cai, H., Zhang, J., Liu, C., Le, T. N., Lu, Y., Feng, F., & Zhao, M. (2024) · Foods · doi:10.3390/foods13050699 · Cited by 58
“Jiang et al. reported that the intestinal FXR activation caused by an HFD diet in mice was involved in abnormal ceramide synthesis, which directly compromised the beige fat thermogenic function and adverse metabolic phenotypes [32].”
BackgroundClinical implications of understanding the association between oxidative stress and pediatric NAFLD
Mann, J. P., Raponi, M., & Nobili, V. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1291340 · Cited by 51
“Intraluminal degradation or oxidation of bile acids causes over activation of enterocyte FXR, which promotes synthesis of ceramides that then drive hepatic de novo lipogenesis [113].”
BackgroundRole of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
Takahashi, S., Tanaka, N., Fukami, T., Xie, C., Yagai, T., Kim, D., Velenosi, T. J., Yan, T., Krausz, K. W., Levi, M., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1263 · Cited by 50
“While intestinal FXR antagonism was recently proposed as a potential strategy for treating obesity, diabetes, and nonalcoholic fatty liver disease,(1,15,37,38) concerns arose about the possibility that enterocyte-targeted FXR inhibitors might promote liver inflammation/injury and tumorigenesis.”
BackgroundSelf-citationDing, L., Zhang, E., Yang, Q., Jin, L., Sousa, K. M., Dong, B., Wang, Y., Tu, J., Ma, X., Tian, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019388118 · Cited by 50
Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity
Zhang, Y.-B., Yan, T., Wang, T., Liu, X., Hamada, K., Sun, D., Sun, Y., Yang, Y., Wang, J., Takahashi, S., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.004 · Cited by 51
Self-citationMicrobial sensing in the intestine
Wan, T., Wang, Y., He, K., & Zhu, S. (2023) · Protein & Cell · doi:10.1093/procel/pwad028 · Cited by 51
Bile acid metabolism in health and ageing-related diseases
Li, X., Fang, C., Zhao, R., Zou, L., Miao, H., & Zhao, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116313 · Cited by 59
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols
Tveter, K. M., Mezhibovsky, E., Wu, Y., & Roopchand, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108457 · Cited by 53
Haczeyni, F., Poekes, L., Wang, H., Mridha, A. R., Barn, V., Geoffrey Haigh, W., Ioannou, G. N., Yeh, M. M., Leclercq, I. A., Teoh, N. C., et al. (2017) · Obesity · doi:10.1002/oby.21701 · Cited by 46
“It remains unclear whether the reduction in adipose inflammatory recruitment produced by OCA treatment in Wt mice is a direct effect of FXR activation on adipogenic factors in adipocytes or whether intestinal FXR could exert beneficial effects on adipose inflammation via such mediators as fibroblast growth factor 15 (…”
BackgroundMetabolic Effects of Bile Acids: Potential Role in Bariatric Surgery
Flynn, C. R., Albaugh, V. L., & Abumrad, N. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.014 · Cited by 48
Chen, J., Zheng, M., Liu, J., Luo, Y., Yang, W., Yang, J., Liu, J., Zhou, J., Xu, C., Zhao, F., et al. (2019) · Obesity · doi:10.1002/oby.22627 · Cited by 46
“Nonetheless, inhibition of FXR signaling by a specific FXR antagonist or elimination of BAs was also capable of improving hepatic steatosis and NASH in mouse experiments (16,17).”
BackgroundSelf-citationLinking liver metabolic and vascular disease via bile acid signaling
Fiorucci, S., & Distrutti, E. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.10.005 · Cited by 49
Dietary and metabolic effects on intestinal stem cells in health and disease
Shay, J. E. S., & Yilmaz, Ö. H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00980-7 · Cited by 63
“Moreover, FXR inhibition decreases ceramide levels in the intestines of mice that are obese and improves metabolic dysfunction associated with obesity such as insulin resistance and hepatic steatosis 138–140 .”
Roles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling
Dawson, P. A. (2017) · Digestive Diseases · doi:10.1159/000450987 · Cited by 47
ENDOCRINOLOGY IN PREGNANCY: Metabolic impact of bile acids in gestation
Fan, H. M., Mitchell, A., & Williamson, C. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1101 · Cited by 49
The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism
Lefort, C., & Cani, P. D. (2021) · Cells · doi:10.3390/cells10020400 · Cited by 42
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Nawrot, M., Peschard, S., Lestavel, S., & Staels, B. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154844 · Cited by 51
Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis
van de Peppel, I. P., Bodewes, F. A. J. A., Verkade, H. J., & Jonker, J. W. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.009 · Cited by 44
“This claim was further supported by a study in which administration of glyco-β-muricholic acid (Gly-MCA), a selective FXR inhibitor, reduced obesity and improved related metabolic abnormalities in mice (76).”
ResultHuang, H., Lee, W., Chen, S., Chen, T.-F., Lee, S., & Chen, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060815 · Cited by 43
“Inconsistently, glycine-β-muricholic acid, as a selective high-affinity FXR inhibitor, inhibits FXR signaling and improves obesity, insulin resistance, and hepatic steatosis in mouse models of obesity [9].”
BackgroundZhou, W., & Anakk, S. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111616 · Cited by 43
Xie, Z., Jiang, H., Liu, W., Zhang, X., Chen, D., Sun, S.-M., Zhou, C., Liu, J., Bao, S., Wang, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02974-0 · Cited by 42
Self-citationNeil, E. S., McGinley, J. N., Fitzgerald, V. K., Lauck, C. A., Tabke, J. A., Streeter-McDonald, M. R., Yao, L., Broeckling, C. D., Weir, T. L., Foster, M. T., et al. (2019) · Nutrients · doi:10.3390/nu11112780 · Cited by 46
“DNA oligo primers were synthesized (Integrated DNA Technologies, Coralville, IA, USA) [19].”
BackgroundMethodJian, Y., Yang, G., Zhang, L., Liang, J., Zhou, H., Wang, Y.-S., & Xu, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30651 · Cited by 45
Zhang, C., Liu, Y., Wang, Y., Ge, X., Jiao, T., Yin, J., Wang, K., Li, C., Guo, S., Xie, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01394 · Cited by 43
Self-citationHalilbasic, E., Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Digestive Diseases · doi:10.1159/000445268 · Cited by 39
Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment
Zaborska, K. E., & Cummings, B. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1092-3 · Cited by 42
Luo, X., Wang, K., & Jiang, C. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.020 · Cited by 45
Self-citationCarino, A., Marchianò, S., Biagioli, M., Fiorucci, C., Zampella, A., Monti, M. C., Morretta, E., Bordoni, M., Giorgio, C. D., Roselli, R., et al. (2019) · Nutrients · doi:10.3390/nu11051132 · Cited by 38
“Indeed, mice feed an HFD–F were characterized by a robust increase in the relative amount of T-βMCA, a relatively potent FXR antagonist [39,40].”
BackgroundBile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
Wu, Y., Zhou, A., Tang, L., Lei, Y., Tang, B., & Zhang, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6138438 · Cited by 45
“Although it was not used for diabetes treatment, its effects in inhibiting bile acid synthesis and improving liver function have been verified in the treatment of metabolic liver diseases [100, 101].”
Tveter, K. M., Villa-Rodríguez, J. A., Cabales, A., Zhang, L., Bawagan, F. G., Duran, R. M., & Roopchand, D. E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001386 · Cited by 42
“TCA was also reported as an FXR agonist; 12 however, this discrepancy does not appear to be due to our experimental conditions as the activities of well-established FXR agonist CDCA and antagonist T β MCA were highly reproducible in our system.”
Zhao, T., Wang, J., He, A., Wang, S., Chen, Y., Lu, J., Lv, J., Li, S., Wang, J., Qian, M., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154771 · Cited by 40
Tang, Y., Fan, Y., Wang, Y., Wang, D., Huang, Q., Chen, T., Cao, X., Wen, C., Shen, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116658 · Cited by 41
Self-citationWang, S., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123211 · Cited by 45
Cheng, L., Chen, T., Guo, M., Liu, P., Qiao, X., Wei, Y., She, J., Li, B., Xi, W., Zhou, J., et al. (2021) · Clinical Science · doi:10.1042/cs20210198 · Cited by 37
“BAs are metabolic sensors that active FXR signaling to control lipid, glucose and energy metabolism [17,20].”
Hu, X., Fan, Y., Li, H., Zhou, R., Zhao, X., Sun, Y., & Zhang, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.766739 · Cited by 41
“Also, direct oral administration of FXR antagonists including ursodeoxycholic acid and GlyMCA can affect bile acid and lipid metabolism (66, 67).”
BackgroundBile acids and salt-sensitive hypertension: a role of the gut-liver axis
Ishimwe, J., Dola, T., Ertuğlu, L. A., & Kirabo, A. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00027.2022 · Cited by 38
Tian, J., Jin, Y.-Q., Yu, E., Sun, J., Xia, Y. L., Zhang, K., Li, Z., Gong, W., Wang, G.-J., & Xie, J. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.736248 · Cited by 34
MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases
Sonne, D. P. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1410 · Cited by 39
Zhao, Y., He, Z., Hao, W., Zhu, H., Liu, J., Ma, K. Y., He, W., & Chen, Z. (2021) · Food & Function · doi:10.1039/d1fo02906a · Cited by 38
Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids
Way, G. W., Jackson, K. G., Muscu, S. R., & Zhou, H. (2022) · Cells · doi:10.3390/cells11081374 · Cited by 35
“Although deficiency or inhibition of FXR has been shown to alleviate obesity in NAFLD mice [138,139], in ALD, it has been shown to cause more damage, and FXR agonists improve ALD [140,141].”
BackgroundFXR and NASH: an avenue for tissue-specific regulation
Henry, Z. R., Meadows, V., & Guo, G. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000127 · Cited by 40
“[97] Intestinal FXR has been shown to increase the expression of genes involved in ceramide synthesis.”
Gao, Y., Chen, Y., Yue, X., He, J., Zhang, R., Xu, J., Zhou, Z., Wang, Z., Zhang, R., & Abliz, Z. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.08.042 · Cited by 35
Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches
Aghara, H., Patel, M., Chadha, P., Parwani, K., Chaturvedi, R., & Mandal, P. (2025) · Mediators of Inflammation · doi:10.1155/mi/6733477 · Cited by 43
“Among these, FXR signaling plays a key role in metabolic regulation across the liver, intestine, and adipose tissues [28].”
Microbiota-derived bile acid metabolic enzymes and their impacts on host health
Ma, H., Wang, K., & Jiang, C. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100265 · Cited by 44
Self-citationQin, H., Xu, H., Yu, L., Yang, L., Lin, C., & Chen, J. (2019) · Food & Nutrition Research · doi:10.29219/fnr.v63.3637 · Cited by 34
Li, C., Zhou, W., Li, M., Shu, X., Zhang, L. R., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111587 · Cited by 35
Wu, J., Qiu, M., Zhang, C., Zhang, C., Wang, N., Zhao, F., Liqiao, L. V., Li, J., Lyu-Bu, A. G. A., Wang, T., et al. (2021) · Food & Function · doi:10.1039/d1fo02208c · Cited by 39
Self-citationZhao, R., Ji, Y., Chen, X., Ma, G., Yao, H., Li, J., Hu, Q., & Zhao, L. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127308 · Cited by 37
Self-citationGao, X., Xie, C., Wang, Y., Luo, Y., Yagai, T., Sun, D., Qin, X., Krausz, K. W., & Gonzalez, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.021 · Cited by 36
“UPLC-ESI-QTOFMS analysis and multivariate data analysis Ultra-performance liquid chromatography coupled quadrupole time-of-flight mass spectroscopy (UPLC-ESI-QTOFMS, ACQUITY UPLC®, Waters) was applied for metabolomic analysis as described [17].”
MethodSelf-citationHS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter
Xu, X., Shi, X., Chen, Y., Zhou, T., Wang, J., Xu, X. Y., Chen, L., Hu, L., & Shen, X. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.016 · Cited by 34
Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism
Lefort, C., Roumain, M., Hul, M. V., Rastelli, M., Manco, R., Leclercq, I. A., Delzenne, N. M., Marzo, V. D., Flamand, N., Luquet, S. H., et al. (2020) · Cells · doi:10.3390/cells9051247 · Cited by 34
“For instance, Jiang and colleagues demonstrated an improvement of glucose metabolism and a reduction of plasma insulin level in mice treated with glycine-β-MCA [66].”
BackgroundThe Potential Role of Gut Microbiota in the Prevention and Treatment of Lipid Metabolism Disorders
He, Y.-J., & You, C. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8601796 · Cited by 35
“An intestine-selective FXR inhibitor can improve obesity and metabolic syndrome in HFD-induced obese mice [73].”
BackgroundZhao, Y., Xu, H., Tian, Z., Wang, X., Xu, L., Li, K., Gao, X., Fan, D., Ma, X., Ling, W., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.014 · Cited by 35
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
“245,246 The UDCA derivative, GUDCA is considered an FXR antagonist.”
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
Self-citationThe delayed effects of antibiotics in type 2 diabetes, friend or foe?
Fu, L., Qiu, Y., Shen, L., Cui, C., Wang, S., Wang, S., Xie, Y., Zhao, X., Gao, X., Ning, G., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0709 · Cited by 36
Waise, T. M. Z., Lim, Y.-M., Danaei, Z., Zhang, S., & Lam, T. K. T. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101132 · Cited by 33
“Furthermore, for the first time to our knowledge, we show that direct short-term inhibition of FXR in the USI enhances nutrient sensing and glucose tolerance in HF rats, consistent with the glucose homeostatic regulations exert by FXR inhibition in the ileum of mice [12,13,21,31].”
BackgroundParaiso, I. L., Tran, T. Q., Magaña, A. A., Kundu, P., Choi, J., Maier, C. S., Bobe, G., Raber, J., Kioussi, C., & Stevens, J. F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643857 · Cited by 35
“In turn, CYP7A1 regulates T-α-MCA and T-β-MCA synthesis, while CYP8B1 is required for TCA synthesis (Jiang et al., 2015; Chiang, 2009; Qi et al., 2015).”
BackgroundMarchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Urbani, G., Morretta, E., Monti, M. C., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159218 · Cited by 36
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
Kamath, S., Chan, N. S. L., & Joyce, P. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70487 · Cited by 42
“35,76,78,83”
Patankar, J. V., Wong, C. K., Morampudi, V., Gibson, W. T., Vallance, B. A., Ioannou, G. N., & Hayden, M. R. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00172.2017 · Cited by 35
“413 However, other groups have also reported that conjugation state of the MCAs 414 dictates binding to FXR in a tissue-specific manner and that the antagonistic activity 415 may also result from FXR-independent mechanisms(17).”
BackgroundGai, Z., Gui, T., Alecu, I., Lone, M. A., Hornemann, T., Chen, Q., Visentin, M., Hiller, C., Häusler, S., & Kullak-Ublick, G. A. (2019) · Liver International · doi:10.1111/liv.14340 · Cited by 31
Paraiso, I. L., Revel, J. S., Choi, J., Miranda, C. L., Lak, P., Kioussi, C., Bobe, G., Gombart, A. F., Raber, J., Maier, C. S., et al. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000341 · Cited by 36
“A bile acid–FXR signaling axis has been shown to control ceramide synthesis in the intestine, as inhibition of intestinal FXR results in the repression of pro-ceramide genes [25, 66].”
BackgroundFiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 30
McGinley, J. N., Fitzgerald, V. K., Neil, E. S., Omerigic, H., Heuberger, A. L., Weir, T. L., McGee, R. J., Vandemark, G. J., & Thompson, H. J. (2020) · Nutrients · doi:10.3390/nu12030593 · Cited by 30
“DNA oligo primers were synthesized (Integrated DNA Technologies, Coralville, IA, USA), sequences are shown in Supplementary Table S3 [48].”
MethodGao, J., Mao, K., Wang, X., Mi, S., Fu, M., Li, X., Xiao, J., Simal‐Gándara, J., & Sang, Y. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02430 · Cited by 32
Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
Helmstädter, M., Kaiser, A., Brunst, S., Schmidt, J., Ronchetti, R., Weizel, L., Proschak, E., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00831 · Cited by 30
Li, Y., Hou, H., Wang, X., Dai, X., Zhang, W., Tang, Q., Dong, Y., Yan, C., Wang, B., Li, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.796590 · Cited by 31
Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma
Guo, Y., Peng, Q., Hao, L., Ji, J., Zhang, Z., Xue, Y., Liu, Y., Gao, Y., Li, C., & Shi, X. (2022) · The FASEB Journal · doi:10.1096/fj.202200171r · Cited by 30
Self-citationVauzour, D., Rodríguez‐Ramiro, I., Rushbrook, S., Ipharraguerre, I. R., Bevan, D., Davies, S. E., Tejera, N., Mena, P. R., de Pascual‐Teresa, S., Rio, D. D., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.002 · Cited by 34
Ren, Q., Chen, Y., Zhou, Z., Cai, Z., Jiao, S., Huang, W., Wang, B., Chen, S., Wang, W., Cao, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01918 · Cited by 30
New insights on intestinal microorganisms and carbohydrate metabolism in fish
Zhang, B., Cai, G.-H., Yang, H., Nie, Q.-J., Liu, Z., & Sun, Y. (2023) · Aquaculture International · doi:10.1007/s10499-023-01262-w · Cited by 36
“Bile acids can enhance glu‑ cose uptake into the liver and lead to storage hepatic glucose by activating intestinal FXR‑ FGF19 axis and increasing the production of GLUT1 receptors (Jiang et al. 2015).”
Tian, F., Chen, T., Xu, W., Fan, Y., Feng, X., Huang, Q. Q., & Chen, J. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300195 · Cited by 31
Wang, G., Cao, L., Li, S., Zhang, M., Li, Y., Duan, J., Li, Y., Hu, Z., Wu, J., Ni, J., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00582-w · Cited by 29
“The dose of ceramide administration (10 mg/kg) was based on well-established protocols 60,61 .”
MethodFujita, K., Iguchi, Y., Une, M., & Watanabe, S. (2017) · Lipids · doi:10.1007/s11745-017-4242-5 · Cited by 31
“In addition, a recent report demonstrated that tauro-β-MCA accumulation in the intestines suppresses intestinal FXR activity and then inhibits ceramide synthesis, which reduces serum ceramide levels and then downregulates hepatic SREBP1cdependent lipogenesis [27].”
BackgroundPotential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease
van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W., & Kuipers, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_233 · Cited by 33
Nuclear receptors and non-alcoholic fatty liver disease: An update
Xiao, Y., Gonzalez, F. J., Huang, M., & Bi, H. (2020) · Liver Research · doi:10.1016/j.livres.2020.03.001 · Cited by 31
Self-citationLiver-derived metabolites as signaling molecules in fatty liver disease
Keles, U., Ow, J. R., Kuentzel, K. B., Zhao, L. N., & Kaldis, P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04658-8 · Cited by 40
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.